The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Despite efforts to curb overdiagnosis of thyroid cancer, the issue has continued to plague U.S. healthcare, according to results from a retrospective, population-based study.

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

German Merck said it plans to combine its scientific ... They will also focus on diabetes, thyroid disorders and cardiovascular diseases, as well as oncology including metastatic colorectal ...

RFK Jr has long expressed views that conflict with scientific evidence, especially on vaccines, and his nomination has provoked opposition from public health experts. But he has also adopted positions ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

It affects both children and adults and occurs in different frequencies across various tumour types, and is more common in sarcomas, brain, kidney and thyroid ... was Merck & Co’s Keytruda ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Papillary Thyroid Cancer. According to GlobalData, Phase II drugs for Papillary Thyroid Cancer have a 29% phase ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.